22 results about "Mucosal vaccine" patented technology

The invention relates to the technical field of immunology, in particular to a haemophilus parasuis disease mucosal vaccine as well as a preparation method and application thereof.The haemophilus parasuis disease mucosal vaccine comprises serum type 4 haemophilus parasuis H0040LV4 and serum type 5 haemophilus parasuis H0014LV5 which are preserved in the China Center for Type Culture Collection (CCTCC) on November 10, 2025 and numbered as CCTCC M 20252516 and CCTCC M 20252517; the bivalent haemophilus parasuis bivalent outer membrane vesicle vaccine prepared by secreting outer membrane vesicles has a good immune protection effect on serum type 4 and type 5 haemophilus parasuis, and compared with a control group, pathological changes of tissues such as lungs and livers of a vaccine immune group are obviously relieved. The vaccine has good immunogenicity, can stimulate comprehensive immune response, induce the organism to generate remarkable specific mucosal immunity, and simultaneously induce cellular immunity and humoral immunity response, and has a wide application prospect.

Methods for stabilizing a liquid vaccine for mucosal use are provided. In certain aspects, the methods may include combining a liquid comprising at least one antigen or antigen encoding composition with a petrolatum carrier.

This invention discloses a method for rapidly constructing a complex of cholera toxin B subunit (CTB) and antigen. The vaccine complex includes a CTB-SpyTag fusion protein and at least one SpyCatcher-antigen fusion protein. It also includes a preparation method for rapidly preparing a CTB5-antigen complex by mixing CTB-SpyTag with the SpyCatcher-antigen. This invention directs the antigen to the side of the CTB pentamer that does not participate in GM1 binding, avoiding steric hindrance interference. It utilizes the SpyTag / SpyCatcher covalent isopeptide bond to obtain highly stable antigen display, reducing antigen shedding during subsequent preparation and storage. It also possesses mucosal targeting and multivalent presentation functions, providing a universal platform technology for rapidly constructing and validating broad-spectrum, combined, or personalized mucosal vaccines.

Provided is an adjuvant for mucosal vaccines comprising a sulfated archaeosome comprising a sulfated glycoarchaeol. The glycoarchaeol may be present as a pharmaceutically acceptable salt. The adjuvant

Disclosed in the present invention are a fatty acid-modified coronavirus antigen and use thereof, pertaining to the field of biomedicine. The fatty acid-modified coronavirus antigen comprises a fatty acid-modified N-terminal cysteine (Cys) and a coronavirus antigen, and may comprise a linking domain. The coronavirus antigen is a coronavirus spike protein (S protein) receptor-binding domain (RBD). The fatty acid-modified coronavirus S protein RBD can self-assemble into nanoparticles. Compared with an RBD without fatty acid modification, the antigen can induce faster and higher humoral immunity by means of injection immunization, and can also induce mucosal immunity and humoral immunity by means of respiratory nebulization immunization, making it a candidate mucosal vaccine with potential medical value.

The invention belongs to the technical field of medicines, and particularly relates to a vaccine preparation strategy taking new coronavirus spike protein as a respiratory mucosa vaccine antigen protein carrier, which is used for preventing respiratory pathogen infection. The novel coronavirus spike protein has good potential as a respiratory mucosa vaccine antigen vector, and can be used for enhancing mucosa and system immune response aiming at a target pathogen.

The invention provides recombinant lactobacillus plantarum for expressing porcine epidemic diarrhea virus S1 protein as well as a preparation method and application of the recombinant lactobacillus plantarum, and belongs to the technical field of preparation of porcine epidemic diarrhea virus vaccines. The recombinant lactobacillus plantarum provided by the invention contains a recombinant vector for expressing a PEDV tS1 fusion gene, and the PEDV tS1 fusion gene comprises a PEDV tS1 structural domain, an endogenous signal peptide 1320 and a dendritic cell targeting peptide DCpep. After the recombinant lactobacillus plantarum provided by the invention is used as a mucosal vaccine through nasal dripping, not only can a codon be prevented from being repeatedly optimized, but also strong cross-species immune response can be induced, pathogen specificity sIgA can be generated, mucosal immunity can be effectively activated, and the induced antibody has the activity of neutralizing PEDV (porcine epidemic diarrhea virus). The recombinant lactobacillus plantarum provided by the invention has a treatment effect.

This invention discloses a rice codon-optimized SARS-CoV-2 Omicron mutant receptor-binding domain dimer protein gene and its applications. The OdiRBD gene consists of two RBD sequences linked by a flexible peptide. Transgenic rice is pulverized and mixed with extraction buffer, then subjected to ultrasonic lysis followed by further extraction and filtration to obtain a crude extract containing OdiRBD. The crude extract containing OdiRBD is then subjected to nickel column chromatography to obtain purified OdiRBD. This method yields plants with stable expression, high extraction efficiency, and is suitable for large-scale production. The rice-derived OdiRBD purified by this method can effectively induce humoral, mucosal, and cellular immune responses in mice via intranasal immunization, and can be used for the development of rice-expressed mucosal vaccines, showing promising application prospects.

This invention relates to a mucosal vaccine composition and to an adjuvant comprising highly deacetylated chitosan for use in a method of immunotherapy, wherein the adjuvant is administered by a mucosal administration.

A non-infectious bacteriophage T4 nanoparticle vaccine composition includes a bacteriophage capsid and at least one antigen displayed on the surface of the capsid or packaged in its interior. The vaccine is administered intranasally and is free of an adjuvant. The antigen is selected from respiratory viruses including coronavirus and influenza.

The invention relates to the field of biological medicine, in particular to a nucleic acid delivery carrier compound formula and application thereof, and the nucleic acid delivery carrier compound formula is prepared from the following components in parts by mole: 5 to 12 parts of HEDMA-Apd-C12, 31.3 to 41.3 parts of D-lin-MC3-DMA, 10 to 28.8 parts of auxiliary phospholipid, 19.2 to 42.7 parts of cholesterol and 1.5 to 2 parts of PEG conjugated lipid. According to the formula, mRNA expressed by efficient protein can be wrapped and used for treating related defect diseases, and specific transfection is achieved in a T cell and NK cell system of a serum-free culture system. Compared with a DLin-MC3-DMA assembled cationic liposome formula and an SM-102 assembled cationic liposome formula, the effect of the formula disclosed by the invention is improved. The research provides a novel efficient and low-toxicity delivery strategy for cell and gene therapy, especially serum-free system CAR-T manufacturing, mucosal vaccine development and the like.

Embodiments of the present disclosure generally relate to compositions of a lyophilized (freeze dried) Listeria strain based therapeutics and a method for lyophilizing compositions of the therapeutics. A Listeria monocytogenes (LM) based vaccine formulation contains a lyophilized powder including a LM bacteria, the LM bacteria comprising at least one therapeutic agent and a lyophilization medium and a delivery composition. A method of forming a Listeria monocytogenes (LM) based vaccine formulation is disclosed. The LM based vaccine formulation includes resuspending an LM stock in a lyophilization medium to form a lyophilization composition, wherein the lyophilization medium comprises at least a lyoprotectant and a buffer component, freezing the lyophilization composition, lyophilizing the lyophilization composition, and forming a lyophilized powder, the lyophilized powder contains a LM bacteria, a lyoprotectant, and a buffer component.

The application belongs to the field of immunology and relates to an mRNA delivery carrier, a preparation method and application of an oral vaccine. A calcium alginate microsphere and a cholic acid-fluorine co-modified polyethyleneimine (DFP) form a double protection system, the compact crosslinked structure of the calcium alginate microsphere resists the acid-base environment of the gastrointestinal tract and nuclease degradation, and the complex formed by the DFP and the mRNA can further prevent the mRNA from being enzymatically degraded. The application provides preparation of an oral mRNA delivery system for activating intestinal mucosal immunity and application of the oral mRNA delivery system in a diarrhea vaccine, provides effective protection against porcine diarrhea coronavirus infection, and provides a new idea for research and development of intestinal mucosal vaccines.

The invention relates to the technical field of medicines, and relates to application of carvedilol in preparation of a novel coronavirus respiratory mucosa vaccine. The novel coronavirus respiratory mucosa vaccine is a vaccine which takes carvedilol as a unique immunologic adjuvant or a composite adjuvant containing capsaicin and is inoculated through a nasal drop or nasal spray way to prevent novel coronavirus infection. The recombinant new coronavirus spike protein is used as an antigen and is mixed with carvedilol, and the mixture is inoculated to a narla golden hamster in a nasal drop manner. Experimental results show that carvedilol can effectively promote a body to generate a specific antibody aiming at spike protein, so that the IgG level in serum is remarkably improved, and IgA response in alveolar lavage fluid is also enhanced. Therefore, a basis is provided for development of carvedilol as a respiratory mucosa vaccine adjuvant.

The invention belongs to the technical field of biological medicine, and relates to a peptide protein kinase C inhibitor and application thereof, in particular to a protein kinase C zeta type novel inhibitor and application thereof as a tissue penetrating agent, especially in the background of cancer prevention and / or treatment or immune response induction, especially mucosal vaccination or anti-opioid drug treatment. The inhibitors are peptides having a total of 5 to 10 amino acids of the structure of formula (I), advantageously useful for inducing transient tissue penetration, in particular for enhancing penetration of large therapeutic molecules, for transmucosal delivery of high molecular weight drugs, avoiding parenteral administration of such drugs.

Methods for stabilizing a liquid vaccine for mucosal use are provided. In certain aspects, the methods may include combining a liquid comprising at least one antigen or antigen encoding composition with a petrolatum carrier.

A non-infections bacteriophage T4 nanoparticle vaccine composition includes a bacteriophage capsid and at least one antigen displayed on the surface of the capsid or packaged in its interior. The vaccine is administered intranasally and is free of an adjuvant. The antigen is selected from respiratory viruses including coronavirus and influenza.

This invention relates to the field of biopharmaceutical technology, specifically to a recombinant pentamer protein, polynucleotide, expression vector, host cell, preparation method, and application. The fusion protein is formed by fusing LTB or its immunogenic functional variant with the pentamer domain of COMP via a flexible linker peptide. This invention constructs the gene of this fusion protein in a eukaryotic expression vector, transfects it into CHO-K1 cells, obtains stable high-expression cell lines through pressure selection, and performs efficient secretory expression using serum-free suspension culture. The resulting protein forms a pentamer under non-reducing conditions. The sIgA level in mouse nasal lavage fluid is significantly higher than that of the antigen alone, confirming its effective activation of local immunity in the respiratory mucosa. This invention utilizes the CHO expression system to achieve large-scale preparation of structurally correct, homogeneous, and endotoxin-free LTB pentamers, which has significant application value in the development of mucosal vaccines, targeted delivery, and diagnostic reagents.

The invention relates to the technical field of medicines, and relates to application of capsaicin in preparation of a novel coronavirus respiratory mucosa vaccine. The novel coronavirus respiratory mucosa vaccine is a vaccine which takes capsaicin as a unique immunologic adjuvant or a composite adjuvant containing capsaicin and is inoculated through a nasal drop or nasal spray way to prevent novel coronavirus infection. The recombinant new coronavirus spike protein is used as an antigen and is mixed with capsaicin, and then the mixture is inoculated to the narla golden hamster in a nasal drop manner. Experimental results show that capsaicin can effectively promote a body to generate a specific antibody aiming at spike protein, so that not only is the IgG level in serum remarkably improved, but also the IgA response in alveolar lavage fluid is enhanced. Therefore, a basis is provided for development of capsaicin as a respiratory mucosa vaccine adjuvant.

This application relates to the biomedical field, specifically to a nucleic acid delivery vector formulation and its application, comprising the following components in molar amounts: HEDMA-Apd-C12 5-12 parts, D-lin-MC3-DMA 31.3-41.3 parts, helper phospholipids 10-28.8 parts, cholesterol 19.2-42.7 parts, and PEG-conjugated lipids 1.5-2 parts. This formulation can encapsulate highly efficient protein-expressing mRNA for the treatment of related defective diseases and achieves specific transfection in serum-free T cell and NK cell systems. Compared with Dlin-MC3-DMA and SM-102 assembled cationic liposome formulations, this formulation shows improved efficacy. This research provides a novel, efficient, and low-toxicity delivery strategy for cell and gene therapy, particularly for serum-free CAR-T manufacturing and the development of mucosal vaccines.

The invention belongs to the field of veterinary virus vaccines, and discloses a nano-emulsion adjuvant suitable for swine influenza virus vaccines and an application of the nano-emulsion adjuvant. The adjuvant disclosed by the invention is prepared from light white oil for injection, span 80, Tween 80, hydroxypropyl methyl cellulose, chitosan oligosaccharide and CpG oligodeoxynucleotide. The adjuvant provided by the invention synchronously enhances humoral immunity, cellular immunity and mucosal immunity by activating innate immunity and adaptive immunity pathways, so that comprehensive immune protection is formed, and multi-dimensional immune response synergistic enhancement is realized. The nano-emulsion adjuvant system is applied to swine influenza vaccine development, especially for optimizing a nasal cavity immune way, and an efficient, convenient and good-compliance mucous membrane vaccination strategy is provided for swine influenza prevention and control.

An adjuvant and a transmucosal vaccine may have a high ability of inducing, through transmucosal administration, secretory IgA in addition to serum IgA and IgG. Such an adjuvant may contain, as an active ingredient, one or more polypeptides selected from (1) a polypeptide having one or two amino acid sequences shown in at least SEQ ID NO: 1, and (2) a polypeptide having 93% or more identity to the amino acid sequence.